VAXNEUVANCE IS RECOMMENDED as an option in the Australian Immunisation Handbook for children and certain adults at increased risk of pneumococcal disease . 1
& me ! for me !
SCAN TO VIEW THE AUSTRALIAN IMMUNISATION HANDBOOK
VAXNEUVANCE is indicated for active immunisation for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes ( 1 , 3 , 4 , 5 , 6A , 6B , 7F , 9V , 14 , 18C , 19A , 19F , 22F , 23F and 33F ) in adults and children from 6 weeks of age . 2 VAXNEUVANCE may not prevent disease caused by S . Pneumoniae serotypes that are not contained in the vaccine . The use of VAXNEUVANCE should be guided by official recommendations . 2
SELECTED SAFETY INFORMATION 2 CONTRAINDICATIONS : Individuals with a history of a severe allergic reaction ( e . g ., anaphylaxis ) to any component of the vaccine or any diphtheria toxoid-containing vaccine .
PRECAUTIONS : Individuals with altered immunocompetence , including those receiving immunosuppressive therapy , may have a reduced immune response to VAXNEUVANCE . The potential risk of apnoea should be considered when administering to infants born prematurely – as the benefit of vaccination is high in this group of infants , vaccination generally should not be withheld or delayed . As with any vaccine , VAXNEUVANCE may not protect all vaccine recipients . The safety and effectiveness of VAXNEUVANCE in children younger than 6 weeks of age have not been established . Pregnancy category B1 .
ADVERSE EFFECTS : Children : Pain , erythema , swelling , induration , decreased appetite , irritability , somnolence , urticaria , elevated body temperature , fatigue , headache , myalgia , injection-site urticaria . Adults : Pain , erythema , swelling , fatigue , headache , myalgia , arthralgia , elevated body temperature , injection site pruritus .
VAXNEUVANCE is not listed on the National Immunisation Program .
Please review the Product Information before prescribing . Product Information is available at www . msdinfo . com . au / vaxneuvancepi or by scanning the QR code .
This medicinal product is subject to additional monitoring in Australia . This will allow quick identification of new safety information . Healthcare professionals are asked to report any suspected adverse events at www . tga . gov . au / reporting-problems
References : 1 . Australian Government , Department of Health and Aged Care . Australian Immunisation Handbook . Pneumococcal disease . Available at : https :// immunisationhandbook . health . gov . au / contents // vaccine-preventablediseases / pneumococcal-disease . Accessed 22 August 2024 . 2 . VAXNEUVANCE Australian Approved Product Information , 31 October 2024 . Copyright © 2024 Merck & Co ., Inc ., Rahway , NJ , USA , and its affiliates . All rights reserved . Merck Sharp & Dohme ( Australia ) Pty Limited . Level 1 – Building A , 26 Talavera Road , Macquarie Park NSW 2113 . AU-PVC-00075 ( v4.0 ). Date prepared : January 2025 . 002706 .